Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (2.848)

11

Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer

enthalten in: Cancer medicine | 2024

von Uekusa, R. | Yokoi, A. | Watanabe, E. | +9

12

Current post-surgical treatment strategies in first-line ovarian cancer

enthalten in: Bulletin du cancer | 2024

von Ouali, K. | Michels, J. | Blanc-Durand, F. | +9

13

Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction : A Case Report

enthalten in: In vivo (Athens, Greece) | 2024

von Endo, Y. | Kamo, N. | Kato, A. | +5

14

Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy

enthalten in: Advances in therapy | 2024

von Rognoni, C. | Lorusso, D. | Costa, F. | +1

15

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

enthalten in: Cancer nanotechnology | 2024

von Baldwin, P. | Yang, S. | Orriols, A. | +3

16

A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers

enthalten in: Cell reports. Medicine | 2024

von Alruwaili, M. | Zonneville, J. | Naranjo, M. | +11

17

Progression-free survival and safety at 3.5 years of follow-up : results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary

enthalten in: Future oncology (London, England) | 2024

von González-Martín, A. | Pothuri, B. | Vergote, I. | +15

18

Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy

enthalten in: Journal of gynecologic oncology | 2024

von Lee, Y. | Shin, Y. | Kim, N. | +6

19

NRG-GY012 : Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

enthalten in: Cancer | 2024

von Rimel, B. | Enserro, D. | Bender, D. | +10

20

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2024

von Teng, Q. | Lei, Z. | Wang, J. | +9